A Study of HA121-28 Tablets in Patients With Medullary Thyroid Carcinoma (MTC)

Summary

This is a single-arm, open-label, multicenter study designed to evaluate the preliminary antineoplastic activity, safety and tolerability of HA121-28 tablets administered orally in patients with medullary thyroid cancer (MTC).

Timeline

Start

2021-07-13

Primary completion

2023-03

Completion

2025-03

Drugs

Indications